Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study
Alex C. Spyropoulos,
Gary E. Raskob,
Theodore E. Spiro,
Wentao Lu,
Yoriko De Sanctis,
John Albanese,
Alexandre Mebazaa,
Elliot S. Barnathan
Affiliations
Alex C. Spyropoulos
Department of Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Feinstein Institute for Medical Research, Manhasset, New York, United States
Gary E. Raskob
Hudson College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Theodore E. Spiro
Clinical Development, Pharmaceuticals, Bayer US LLC, Whippany, New Jersey, United States
Wentao Lu
Janssen Research & Development, LLC, Raritan, New Jersey, United States
Yoriko De Sanctis
Clinical Development, Pharmaceuticals, Bayer US LLC, Whippany, New Jersey, United States
John Albanese
Janssen Research & Development, LLC, Raritan, New Jersey, United States
Alexandre Mebazaa
Department of Anesthesia and Critical Care, University of Paris, Paris, France
Elliot S. Barnathan
Janssen Research & Development, LLC, Raritan, New Jersey, United States
This post hoc subgroup analysis examined efficacy and safety outcomes with extended thromboprophylaxis rivaroxaban compared with in-hospital enoxaparin in 2,078 patients from the MAGELLAN study who had a hospitalization for heart failure or a history of heart failure and a lower risk of bleeding. A significant 36% reduction in the composite endpoint of asymptomatic proximal deep vein thrombosis (DVT) in the lower extremity, symptomatic DVT in the lower extremity (proximal or distal), symptomatic nonfatal pulmonary embolism, and venous thromboembolism-related death was observed with rivaroxaban. Major bleeding was low in both groups and not significantly increased with rivaroxaban.
